Application note: A novel solution to expedite antibody discovery
Posted: 29 November 2018 | IntelliCyt Corporation | No comments yet
With breakthroughs in molecular engineering and antibody humanisation, monoclonal antibodies (mAb) are one of the fastest-growing classes of biopharmaceuticals for multiple clinical indications including cancer, cardiovascular disease, autoimmune disorders and infectious disease. Most therapeutic antibody candidates are initially generated using hybridoma technology or primary B-cell screening after antigen immunisation.
Please complete the form below in order to download this application note:
Related content from this organisation
- Whitepaper: Addressing the challenges in biologics discovery with advanced flow cytometry
- Article: Immuno-oncology: Pushing the frontier of discovery through advanced high throughput flow cytometry
- Application note: A kinase inhibitor phenotypic screen using a multiplex T Cell activation assay
- Training and development in flow cytometry and other core technologies
- Expert view: Opportunities in flow cytometry
Related topics
Antibodies, Assays, Biopharmaceuticals, Cell Cultures, Cell-based assays, Disease Research, Enzymes, Molecular Biology, Screening
Related organisations
IntelliCyt Corporation